Overview

* Sanara MedTech ( SMTI ) Q2 revenue rises 28% yr/yr, beating analyst expectations

* Company reports Q2 net loss of $2 mln, narrowing from previous year

* Sanara to evaluate strategic alternatives for Tissue Health Plus subsidiary

Outlook

* Sanara projects cash investment in THP strategy between $5.5 mln and $6.5 mln

* Company evaluating strategic alternatives for Tissue Health Plus subsidiary

* Sanara aims to capitalize on growth opportunities in Sanara Surgical segment

Result Drivers

* SOFT TISSUE REPAIR - Revenue growth driven by increased demand for CellerateRX Surgical and BIASURGE products

* SANARA SURGICAL EXPANSION - Growth attributed to expanding distributor network and penetration into new healthcare facilities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $25.80 $25.10

Revenue mln mln (2

Analysts

)

Q2 EPS -$0.23

Q2 Net -$2 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Sanara Medtech Inc ( SMTI ) is $49.00, about 43.9% above its August 12 closing price of $27.47

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)